ADAM32 Oncogene in Hepatoblastoma Is Regulated by IGF2BP2

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Membrane proteins a disintegrin and metalloproteases (ADAMs) are implicated in various human carcinomas.
• ADAM32 is notably overexpressed in hepatoblastoma (HBL), contributing to its oncogenic properties.
• The regulatory mechanisms of ADAM32, particularly under hypoxia, remain largely undetermined.

Purpose of the Study:

• To investigate the regulatory mechanisms of ADAM32 expression in hepatoblastoma (HBL) under hypoxic conditions.
• To explore the potential role of hypoxia-inducible factor (HIF) in regulating ADAM32.
• To identify novel molecular targets for HBL therapy.

Main Methods:

• Exposure of HBL, breast, and lung cancer cell lines to hypoxic conditions (1% O2).
• Analysis of ADAM32 gene and protein levels, and promoter activity.
• Microarray analysis to identify related molecules, including m6A-related proteins.
• Gene knockdown experiments for HIF1A and IGF2BP2.

Main Results:

• Hypoxia increased ADAM32 levels in HepG2, MCF7, and MDA-MB-231 cells, but not in HUH-6 or lung cancer lines.
• ADAM32 promoter activity in HepG2 cells remained unchanged under hypoxia, suggesting post-transcriptional regulation.
• IGF2BP2 levels correlated with ADAM32 levels and were reduced by HIF1A knockdown.
• IGF2BP2 knockdown decreased ADAM32 expression and attenuated its hypoxic induction.

Conclusions:

• The oncogenic gene ADAM32 is regulated by IGF2BP2, particularly under hypoxic stress.
• IGF2BP2 acts as a key mediator in the hypoxic regulation of ADAM32.
• IGF2BP2 presents a promising molecular target for developing novel anticancer therapies for HBL.